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Abstract
Objective: Recommendations on the frequency of self-monitoring of blood glucose (SMBG) vary widely among physicians
treating patients with type 2 diabetes (T2D). Aim of this study was to investigate two testing regimen of SMBG in patients
with stable metabolic control.
Research Design and Methods: Patients with T2D treated with oral antidiabetic drugs were randomized to two groups:
either one SMBG (low) or four SMBG (high) per week. Subjects were followed up after 3, 6 and 12 months. Primary outcome
parameter was the change in HbA1c between baseline and 6 months. Primary outcome criterion was tested by a one-sided
t- test for non- inferiority. Secondary outcome parameters were safety, compliance and HbA1c at 3 and 12 months.
Results: There were no differences in the 202 subjects for demographic and sociodemographic parameters and drug
treatment. HbA1c (%) at baseline was similar in both groups (7.261.4 vs. 7.261.0). Non- inferiority was demonstrated for the
low group (p=0.0022) with a difference from baseline to 6 months of 0.24 in the low and of 0.16 in the high group.
Compliance with the testing regimen was 82–90% in both groups. There were no statistical significant differences for
compliance, HbA1c at 3 and 12 months and serious adverse events (SAE).
Conclusion: One SMBG per week is as sufficient and safe as four SMBG per week to maintain HbA1c in non-insulin treated
T2D close to metabolic target. The results of this study are in contrast to current international consensus guidelines.
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Introduction
Self-monitoring blood glucose (SMBG) improves glycaemic
control in patients with type 1 diabetes [1] and possibly also in
insulin-treated type 2 diabetes (T2D) [2], especially when treated
with multiple insulin injections per day [3]. However, the value
and frequency of SMBG in non-insulin-treated patients with T2D
is a matter of controversy.
A consensus opinion among a group of experts from the UK
suggested that patients with T2D using oral antidiabetic drugs
(OAD) should monitor their blood glucose at least once daily,
varying the time of testing between fasting, preprandial and
postprandial levels during the day [4]. A global consensus
conference on SMBG recommended eleven measurements a week
in these patients [5] and another recent consensus conference
noted that patents with T2D on OAD may use SMBG but specific
recommendations with respect to frequency were not made [6].
A cross-sectional and longitudinal study of patients with T2D in
Australia showed that HbA1c was not significantly different
between SMBG users and nonusers, either overall or within
diabetes treatment groups such as diet, OAD or insulin, with or
without OAD [7]. Although such observational data can be useful
in determining the effect of an intervention [8], conclusive
evidence of this assumption is not available from randomized
controlled trials.
A recent study reported on the effect of a more and less
intensive diabetes education combined with recommendations on
the frequency of SMBG in patients with T2D [9]. They found that
a more intensive education did not result in an improved HbA1c
(%) compared to standard information and care.
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e3087Our study was designed to strictly test the effect of the frequency
of SMBG without changing the other diabetes management.
Our hypothesis was that one SMBG measurement a week in a
stable phase of metabolic control close to glycemic target is no less
effective than more measurements a week with regard to metabolic
control, hypoglycaemia and/or hyperglycemias, or adverse events
(AE).
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1 and Protocol S2.
Study design
A prospective multi-centre randomized controlled trial was
performed evaluating non-inferiority of low vs. high frequencies of
SMBG with respect to metabolic control T2D. The study was
approved by the ethical committees of all six institutions
participating, and all patients provided their written informed
consent.
Study population
Patients with T2D treated with one or more OAD (not
combined with insulin therapy and stable oral medication for the
last three months) aged between 35 and 80 years were enrolled.
Patients with following conditions were excluded: type 1 diabetes,
advanced renal insufficiency (creatinine level at $2.5 mg/dl), at
least two episodes of hypoglycaemia requiring external support
within the previous three months, one or more severe metabolic
events (hypoglycemic shock, hyperosmolar coma, inpatient stay
due to severe hyperglycaemic events) within the past three months,
pregnancy, severe impairment of vision or communication
problems due to language.
All patients had received a structured education on diabetes
mellitus and instructions on SMBG in practice before the start of
the study, and were not specifically re-educated.
Originally, it was planned to establish a second trial arm with
insulin treated patients, comparing one measurement a week (low
group) with 11 measurements a week (high group). Due to poor
recruitment this arm was terminated early by the trial steering
committee. The reasons for poor recruitment were mainly changes
in diabetes treatment in Germany due to a move from pre-mixed
insulin to a different type of insulin treatment.
Study intervention
Patients were randomly assigned to two strategies of SMBG.
Low group: SMBG with one measurement a week and additional
measurement in the event of suspected hypoglycaemia or severe
hyperglycaemia or high group: four measurements a week on
Tuesdays, Thursdays and one day of the weekend before dinner
and one additional measurement before lunch, and also additional
measurement in the event of suspected hypoglycaemia or severe
hyperglycaemia. Hypoglycaemia was defined as an
SMBG,3.2 mMol/L (,60 mg/dl). Severe hypoglycaemia was
defined as any hypoglycaemia with the need for assistance by
another person.
The randomization list was generated and centrally applied
with concealment by the Coordination Centre for Clinical Trials
with the use of randomly selected block sizes of 4, 6 and 8 patients
stratified according to centre.
In our case-management approach, all patients were asked to
report back to their physician in the event of inappropriate
diabetes control according to the targets set between the patient
and his or her doctor.
Evaluation and follow-up
Potential study patients were screened according to inclusion
and exclusion criteria. After randomization, patients were
instructed on the strategy of SMBG to be applied for a period
of 6 months (formal instruction, written instruction, patient diary,
delivery of equipment for measuring blood glucose). Patients were
evaluated at the initial visit and after 3 and 6 months by clinical
investigation, assessment of (serious) adverse events, quality of life
(at baseline and at 6 months only), compliance with intervention,
change in diabetes treatment, socioeconomic effects and measure-
ment of HbA1c. After 12 months only HbA1c was assessed. In
addition, blood glucose measurements were documented by the
patient in a diary, and the data from the first week each month
were used to assess intervention compliance from the patient’s
viewpoint. Compliance with treatment was defined as follows:
maximal deviation of one measurement from the allocated
frequency (e.g. 3 to 5 in the high group, 0 to 2 in the low group).
Trial outcomes
The primary outcome criterion was the change in HbA1c levels
between baseline and six months after enrolment. Secondary
outcomes were number and type of hypoglycaemic and hypergly-
caemic events, quality of life, compliance and satisfaction with
interventions, socioeconomic effects and HbA1c after 3 and 12
months. Data on quality of life, satisfaction with intervention and
on the socioeconomic background will not be presented in this
paper.
Statistical analysis
The study was designed to test non- inferiority of the low group
compared to the high group. Sample-size calculation was based on
data from the German Diabetes Centre (590 patients, mean value
(standard deviation) of HbA1c: 9.9561.83), a one-sided t-test for
non-inferiority assuming an acceptable deviation of 0.5% for the
difference in HbA1c levels between baseline and 6 months,
statistical power of 80% and an alpha error of 5% leading to an
estimated sample size of 167 patients per group. Taking drop-outs
into consideration (e.g. informed consent withdrawn, lost to
follow-up), sample size was calculated at 400, stratified into two
strata: patients with oral medication (n=200) and patients with
insulin treatment (n=200). All analyses were performed according
to intention to treat and included all randomized patients
excluding the drop-outs. The primary outcome criterion was
tested by a one-sided t-test for non-inferiority. The alternative
hypothesis was stated as follows: the difference in the low group is
equal to or better than in the high group, taking a deviation of
0.5% into consideration [10]. Comparability between study
groups and secondary endpoints were investigated by chi-square
test for qualitative and t-test, Mann- Whitney- test for quantitative
data.
Results
A total of 202 patients from six centres underwent randomiza-
tion in the oral group between Dec 2003 and Oct 2005; 100 were
randomly assigned to the low and 102 to the high group. There
were 12 drop-outs in the low and 11 drop-outs in the high group
(Fig. 1). The baseline characteristics in the two groups were similar
(Table 1, 2). Mean diabetes duration was 7.866.4 years in the low
and 8.266.5 in the high group.
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Compliance with the assigned frequency of SMBG was
measured from the doctor’s and the patient’s viewpoint (Table 3).
Compliance in the low group assessed by the doctor was 61% at 3
months and 73% at 6 months. In the high group, compliance to
the SMBG regimen assigned was 77% at 3 months and 83% at 6
months. Analysis of each patient’s diary revealed compliance in
82–83% (0 to 3 months) and 85–88% (4 to 6 months) in the low
group and 87–90% and 84–88% in the high group. A statistical
significant difference was observed according to doctor’s assess-
ment at 3 months (p,0.03).
Clinicians were asked to record all AE’s and SAE’s according to
Good Clinical Practice (GCP). The number and type of SAE and
AE was similar between the groups except for hypoglecaemia,
which was increased in the high group (Table 4). Twenty patients
from the low group and fifteen in the high group showed SAE. No
hypoglycaemic shock or hyperosmolar coma occurred. Inpatient
hospital treatment was necessary in 19 patients in the low group
and 14 in the high group. There was one death in the low and one
death in the high group. Both deaths were unrelated to the study
intervention (pancreatic cancer, heart failure).
Outcome
HbA1c at baseline was similar in both groups (7.261.4 vs.
7.261.0) (Table 4). The primary outcome criterion (difference of
HbA1c value at baseline and after 6 months) was assessed in 178
patients (low group: n=87, high group: n=91); non-inferiority
was demonstrated for the low group (p=0.0022) with a mean
difference of 0.24 in the low and of 0.16 in the high group. In
addition, no statistically significant differences in HbA1c values
at 3 and 12 months were observed (Table 4). There were no
statistically significant differences between the groups with
Figure 1. Flow of participants in the trial (according to CONSORT statement). * with respect to primary outcome criterion HbA1c.
doi:10.1371/journal.pone.0003087.g001
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treatment, or days off work) and changes in diabetes treatment
(Table 4).
Discussion
To our knowledge, this is the first randomized, controlled
prospective multi-centre trial on the frequency of SMBG in
patients with T2D treated with OAD with a strict focus on the
specific impact of the frequency of SMBG. Patients in this cohort
were in a stable phase of T2D close to glycemic target and they
had been on the same anti-diabetic treatment for at least three
months. In a large observational cohort study (ROSSO), we
recently demonstrated that patients with T2D who apply SMBG
had better outcomes in terms of morbidity and mortality than
patients that did not [11]. However, the database from this cross-
sectional study did not allow to provide any answer to the optimal
frequency of SMBG in T2D.
The need for SMBG in patients with T2D has been discussed
controversially. A recently published review of randomized
Table 1. Characteristics of the patients.
Characteristic Intervention P Value
Low High
(N=100) (N=102)
Age - yr (mean6SD) 61.7611.7 61.069.0 0.68
Sex
- male 60/100 (60%) 65/102 (64%) 0.66
- female 40/100 (40%) 37/102 (36%)
Duration of diabetes -y r 7 . 8 66.4 8.266.5 0.71
History
- coronary heart disease 19/100 (19%) 16/101 (16%) 0.58
- myocardial infarction 8/100 (8%) 11/102 (11%) 0.63
- stroke 2/100 (2%) 2/102 (2%) 1.00
- peripheral arterial disease (PAD) 13/100 (13%) 14/102 (14%) 1.00
- other serious disease 34/100 (34%) 28/102 (28%) 0.36
- diabetic nephropathy 2/100 (2%) 3/102 (3%) 1.00
- diabetic neuropathy 25/100 (25%) 21/102 (21%) 0.50
- diabetic retinopathy 2/100 (2%) 4/102 (4%) 0.68
- relevant hypoglycemia* 3/100 (3%) 4/102 (4%) 1.00
- relevant hyperglycemia* 6/100 (6%) 3/102 (3%) 0.32
HbA1c -% 7 . 2 61.4 7.261.0 0.53
Nationality
- german 84/98 (86%) 89/102 (87%) 0.84
- other 14/98 (14%) 13/102 (13%)
Graduation
- none 3/96 (3%) 1/102 (1%)
- elementary school 46/96 (48%) 44/102 (43%)
- secondary school 12/96 (12%) 17/102 (17%)
- advanced technical college
qualification
11/96 (11%) 15/102 (15%)
- higher education entrance
qualification
22/96 (23%) 20/102 (20%)
- other 2/96 (2%) 5/102 (5%)
Marital status
- single 4/98 (4%) 6/102 (6%)
- married 72/98 (73%) 70/102 (69%) 0.77
- living separate 4/98 (4%) 7/102 (7%)
- divorced 11/98 (11%) 9/102 (9%)
- widowed 7/98 (7%) 10/102 (10%)
Employment Situation
- employed 16/98 (16%) 26/101 (26%)
- part time employed 6/98 (6%) 3/101 (3%)
- old-age pension 42/98 (43%) 41/101 (40%)
- early retired 17/98 (17%) 13/101 (13%) 0.48
- unemployed/short-time work 8/98 (8%) 10/101 (10%)
- housewife 7/98 (7%) 4/101 (4%)
- other 2/98 (2%) 4/101 (4%)
*within previous three months.
doi:10.1371/journal.pone.0003087.t001
Table 2. Characteristics of the patients.




- Acarbose 1/99 (1%) 3/102 (3%) 0.62
- Glibenclamide 23/99 (23%) 19/102 (19%) 0.42
- Glimepirid 25/99 (25%) 29/102 (28%) 0.61
- Gliquidon 0/99 (0%) 1/102 (1%) 1.00
- Glyburide 0/99 (0%) 1/102 (1%) 1.00
- Metformin 70/99 (71%) 76/102 (75%) 0.55
- Nateglinide 2/99 (2%) 1/102 (1%) 0.62
- Pioglitazone 3/99 (3%) 2/102 (2%) 0.68
- Repaglinide 7/99 (7%) 10/102 (10%) 0.49
- Rosiglitazone 9/99 (9%) 5/102 (5%) 0.24
*one patient with missing data.
doi:10.1371/journal.pone.0003087.t002
Table 3. Assessment of compliance.




- 3 months 57/92 (61%) 71/92 (77%) 0.03
- 6 months 62/85 (73%) 75/91 (83%) 0.14
Patients diary*
3 months
- first week in month 1 72/88 (82%) 83/95 (87%) 0.31
- first week in month 2 73/88 (83%) 83/95 (87%) 0.41
- first week in month 3 72/88 (82%) 85/95 (90%) 0.30
6 months
- first week in month 4 73/86 (85%) 77/92 (84%) 0.84
- first week in month 5 73/84 (87%) 80/91 (88%) 1.00
- first week in month 6 73/83 (88%) 77/92 (84%) 0.82
*at most one measurement less or more than defined.
doi:10.1371/journal.pone.0003087.t003
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helpful in non-insulin-treated patients with T2D, but the
methodological quality of the studies analyzed was considered to
be low [12]. Welschen and colleagues defined nine quality criteria
that should ideally be met in this type of study. In their review on
the literature concerning SMBG, they found 1572 citations, but
only six studies were considered as appropriate for further analysis
[13–18]. However, the design of these six studies only met 5, 5, 5,
5, 6, or 7 out of nine methodological quality criteria. Drawbacks
were, among others, failure to conceal treatment allocation (all 6),
blinding of the outcome assessor to the intervention [13–16,18],
unaccounted or unacceptable withdrawal or drop-out rate [18], or
failure to include an intention-to-treat analysis [13–16]. The
conclusions drawn from these studies are limited. All of the above
quality criteria except blinding of the outcome assessor were met
in our study.
We considered one SMBG measurement as clinically important
in order to allow the patient to detect unexpected metabolic
deterioration between doctor’s visits. Four SMBG measurements a
week in our high group is by far less than the eleven measurements
a week that were suggested by a global consensus panel [5]. The
decision to suggest a lower number of SMBG in patients with T2D
treated with OAD and an HbA1c close to target was based on our
own experience in outpatient care of patients with T2D. There is
also a substantial disparity between the actual and recommended
frequency of SMBG testing. A previous analysis of data from
German health care providers demonstrated that patients with
T2D on insulin therapy or on OAD have a test strip use of 1.8 and
0.8 strips a week, respectively [19]. It is also common experience
that patients with HbA1c close to target may not show much
change, and differences between groups would most probably be
minimal [20].
Our primary endpoint of change in HbA1c demonstrated non-
inferiority in the low compared to the high group. One concern we
had with respect to the performance of the study was that patients
assigned to the low group would measure more frequently and
patients in the high group would measure less frequently.
However, most patients in the two groups kept a high level of
compliance to their assigned testing regimen as assessed by patient
diary.
As mentioned above, our study was designed to strictly evaluate
the effect of the frequency of SMBG on metabolic control without
mixing this tool with different education procedures or intensities
in diabetes management. In the study by Farmer et al. [9] it
appeared that only about half of the patients in the more intensive
group followed the recommendations regarding SMBG and the
other performed less than 2 SMBG per week. It may be critisized
that the failure to show an effect on HbA1c in this study is due to a
lack of adherence to the study regimen. In our trial, however, the
adherence in both groups, i.e. low and high frequency of SMBG,
was as high as 82–90%.
No differences were observed with respect to AE’s and SAE’s,
except for hypoglycaemia, which occurred more often in the high
group probably due to the higher frequency of measurements.
Although our data show no advantage of more than one SMBG
measurement a week in non-insulin treated T2D patients it is
important to emphasize that these results only refer to patients
with stable metabolic control and without any necessity of
changing antidiabetic medication. The conclusions drawn from
our study do not refer to patients with newly diagnosed T2D or
patients with intercurrent diseases disturbing metabolic control.
Although prospective controlled trials are still missing to this point
a change in the treatment regimen and frequency of SMBG
measurements may be necessary in such patients [5].
Conclusion
This study shows that in patients with T2D treated with OAD
one SMBG measurement a week is not associated with any
deterioration in metabolic control (HbA1c) or therapeutic safety as
compared to four measurements a week. Under study conditions
compliance for a low frequency of SMBG was surprisingly high.
Table 4. Outcome and Safety.






{ (valid observations) 7.261.4 (100) 7.261.0 (102) 0.92*
- 3 months
mean6SD (valid observations) 6.961.2 (93) 6.960.7 (95) 0.66*
- 6 months
mean6SD (valid observations) 6.961.2 (87) 7.060.8 (91) 0.53*
- 12 months
mean6SD (valid observations) 6.961.0 (82) 7.161.0 (86) 0.10*
Health care utilization
between 0–3 months
- physician visit 65/89 (73%) 68/92 (74%) 1.00
- inpatient stay** 13/90 (15%) 7/92 (8%) 0.16
- incapacity to week 11/86 (13%) 10/90 (11%) 0.81
between 4–6 months
- physician visit 67/85 (79%) 61/91 (67%) 0.09
- inpatient stay** 11/87 (13%) 12/91 (13%) 1.00
- incapacity to week 13/83 (16%) 13/85 (15%) 1.00
Change from oral hypoglycaemic
agents to insulin 5/100 (5%) 9/102 (9%) 0.41
- between 0–3 months 4/100 (4%) 6/102 (6%) 0.75
- between 4–6 months 1/100 (1%) 3/102 (3%) 0.62
Adverse Events
- relevant hypoglycemia
- one event 1/100 (1%) 9/102 (9%) 0.02
- several events 4/100 (4%) 9/102 (9%) 0.25
- relevant hyperglycemia 1/100 (1%) 1/102 (1%) 1.00
- deterioration neuropathy 0/100 (0%) 0/102 (0%) 1.00
- deterioration retinopathy 0/100 (0%) 0/102 (0%) 1.00
- deterioration nephropathy 0/100 (0%) 0/102 (0%) 1.00
- multiple 6/100 (6%) 4/102 (4%) 0.54
- other 7/100 (7%) 3/102 (3%) 0.21
Serious Adverse Events
- hypoglycaemic shock 0/100 (0%) 0/102 (0%) 1.00
- hyperosmolar coma 0/100 (0%) 0/102 (0%) 1.00
- other 20/100 (20%) 15/102 (15%) 0.58
- inpatient stay 19/100 (19%) 14/102 (14%) 0.57
- death 1/100 (1%) 1/102 (1%) 1.00
*t- Test.
{SD=Standard Deviation.
**Hospital, treatment at a health resort, rehabilitation, others.
doi:10.1371/journal.pone.0003087.t004
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in considerable cost-savings and it would be very important for the
sake of type 2 diabetic patients not to have to measure SMBG
more than once weekly.
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